KTTA logo

PASITHEA THERAPEUTICS CORP

KTTANASDAQ
πŸ† #4585 by market capEarnings Mar 29US Equity
$0.48β–Ό $0.00 (βˆ’0.48%)
Market closed Β· at close
πŸ””
Track KTTA
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 0.5%
7dβ–Ό 7.5%
14dβ–Ό 16.8%
30dβ–² 19.6%
ytdβ–Ό 63.2%
1yβ–² 65.1%
🏦Market Cap
$16M
Small Cap
πŸ“ˆRevenue Growth (YoY)
740.5%
High Growth
πŸ“ŠGross Margin
100.5%
High
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
26.8x
Expensive
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$0.47 – $0.48
52-Week Range
$0.28 – $2.06
Volume (shares)
100,722
Avg Volume (shares)
β€”
Shares Outstanding
33.4M
Next Earnings
2027-03-29

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
β€”
P/S Ratio
26.8x
EPS (TTM)
$-1.48
Dividend Yield
β€”
Dilution (1yr)
+541.5%
KTTA logo

PASITHEA THERAPEUTICS CORP

KTTA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$21Mβ–² +46.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$15Mβ–² +9.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
7.0Mβ–² +541.5% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$55Mβ–² +$48M YoY
StockOtter Β· stockotter.space

About PASITHEA THERAPEUTICS CORP

Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

BenzingaΒ·9d ago

Pasithea's PAS-004 Shrinks Skin Tumors in All 15 Evaluable Patients

Pasithea Therapeutics Corp. (NASDAQ:KTTA) on Friday shared positive clinical data from its Phase 1/1b study of PAS-004 in adults with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (PN) and cutaneous n

GlobeNewsWireΒ·9d ago

Pasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activity in Plexiform Neurofibromas at the 2026 European Neurofibromatosis Conference

Pasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activi

GlobeNewsWireΒ·19d ago

Pasithea Therapeutics Announces FDA Clearance of IND for PAS-004 in Neurofibromatosis Type 1 (NF1)-Associated Cutaneous Neurofibromas (cNF)

β€” FDA clearance allows Pasithea to advance PAS-004 for NF1-associated cNF, a condition affecting over 95% of people with NF1 and for which there are currently no FDA-approved systemic therapies . β€” MIAMI, Nov. 03, 2026 (

GlobeNewsWireΒ·25d ago

Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026

MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (β€œPasithea” or the β€œCompany”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibit

GlobeNewsWireΒ·Oct 23

Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026

-- Prolonged Stable Disease: PAS-004 achieved prolonged stable disease in a heavily pre-treated population, with four patients on PAS-004 for more than 300 days, including two who continue on once daily PAS-004 for over

Defense WorldΒ·Oct 4

Pasithea Therapeutics (NASDAQ:KTTA) Shares Down 2.7% – Time to Sell?

Pasithea Therapeutics Corp. (NASDAQ: KTTA - Get Free Report) shares dropped 2.7% on Friday. The company traded as low as $0.4748 and last traded at $0.4760. Approximately 59,809 shares were traded during mid-day trading,